« Return to News | Awards & Advancement

Array BioPharma names Michael Needle as chief medical officer

Friday, March 22, 2013 11:14 AM

Array BioPharma, a biopharmaceutical company focused on targeted small molecule drugs to treat cancer, has appointed Michael N. Needle, M.D., as its chief medical officer. 

Needle, a board certified hematologist/oncologist, will oversee clinical development across Array BioPharma's pipeline, including its two wholly-owned cancer drugs, ARRY-520 for multiple myeloma and ARRY-614 for myelodysplastic syndromes, as well as collaborate with strategic partners to advance late-stage programs.

Needle has more than 14 years of pharmaceutical industry experience in drug development and regulatory affairs.  He most recently served as the chief medical officer of the Multiple Myeloma Research Foundation and Consortium (MMRF). Prior to his tenure at MMRF, he held multiple vice president level positions at Celgene in clinical R&D in oncology, strategic medical business development and pediatric strategy. Needle also served as the vice president of clinical affairs at ImClone Systems.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.